363 related articles for article (PubMed ID: 34724115)
1. GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients.
Yu L; Huang L; Lin D; Lai X; Wu L; Liao X; Liu J; Zeng Y; Liang L; Zhang G; Wang B; Wu Z; Tao S; Liu Y; Jiao C; Chang LJ; Yang L
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2643-2652. PubMed ID: 34724115
[TBL] [Abstract][Full Text] [Related]
2. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
Del Bufalo F; De Angelis B; Caruana I; Del Baldo G; De Ioris MA; Serra A; Mastronuzzi A; Cefalo MG; Pagliara D; Amicucci M; Li Pira G; Leone G; Bertaina V; Sinibaldi M; Di Cecca S; Guercio M; Abbaszadeh Z; Iaffaldano L; Gunetti M; Iacovelli S; Bugianesi R; Macchia S; Algeri M; Merli P; Galaverna F; Abbas R; Garganese MC; Villani MF; Colafati GS; Bonetti F; Rabusin M; Perruccio K; Folsi V; Quintarelli C; Locatelli F;
N Engl J Med; 2023 Apr; 388(14):1284-1295. PubMed ID: 37018492
[TBL] [Abstract][Full Text] [Related]
3. Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma.
Liu Z; Zhou J; Yang X; Liu Y; Zou C; Lv W; Chen C; Cheng KK; Chen T; Chang LJ; Wu D; Mao J
Mol Cancer; 2023 Jan; 22(1):3. PubMed ID: 36617554
[TBL] [Abstract][Full Text] [Related]
4. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.
Heczey A; Louis CU; Savoldo B; Dakhova O; Durett A; Grilley B; Liu H; Wu MF; Mei Z; Gee A; Mehta B; Zhang H; Mahmood N; Tashiro H; Heslop HE; Dotti G; Rooney CM; Brenner MK
Mol Ther; 2017 Sep; 25(9):2214-2224. PubMed ID: 28602436
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma.
Tomida A; Yagyu S; Nakamura K; Kubo H; Yamashima K; Nakazawa Y; Hosoi H; Iehara T
Cancer Sci; 2021 Oct; 112(10):4026-4036. PubMed ID: 34382720
[TBL] [Abstract][Full Text] [Related]
6. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
[TBL] [Abstract][Full Text] [Related]
7. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.
Chen Y; Sun C; Landoni E; Metelitsa L; Dotti G; Savoldo B
Clin Cancer Res; 2019 May; 25(9):2915-2924. PubMed ID: 30617136
[TBL] [Abstract][Full Text] [Related]
8. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
9. Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers.
Gargett T; Truong NTH; Gardam B; Yu W; Ebert LM; Johnson A; Yeo ECF; Wittwer NL; Tapia Rico G; Logan J; Sivaloganathan P; Collis M; Ruszkiewicz A; Brown MP
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38754916
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma.
Straathof K; Flutter B; Wallace R; Jain N; Loka T; Depani S; Wright G; Thomas S; Cheung GW; Gileadi T; Stafford S; Kokalaki E; Barton J; Marriott C; Rampling D; Ogunbiyi O; Akarca AU; Marafioti T; Inglott S; Gilmour K; Al-Hajj M; Day W; McHugh K; Biassoni L; Sizer N; Barton C; Edwards D; Dragoni I; Silvester J; Dyer K; Traub S; Elson L; Brook S; Westwood N; Robson L; Bedi A; Howe K; Barry A; Duncan C; Barone G; Pule M; Anderson J
Sci Transl Med; 2020 Nov; 12(571):. PubMed ID: 33239386
[TBL] [Abstract][Full Text] [Related]
11. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
[TBL] [Abstract][Full Text] [Related]
12. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.
Heczey A; Liu D; Tian G; Courtney AN; Wei J; Marinova E; Gao X; Guo L; Yvon E; Hicks J; Liu H; Dotti G; Metelitsa LS
Blood; 2014 Oct; 124(18):2824-33. PubMed ID: 25049283
[TBL] [Abstract][Full Text] [Related]
13. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
14. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
[TBL] [Abstract][Full Text] [Related]
15. Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.
Long AH; Highfill SL; Cui Y; Smith JP; Walker AJ; Ramakrishna S; El-Etriby R; Galli S; Tsokos MG; Orentas RJ; Mackall CL
Cancer Immunol Res; 2016 Oct; 4(10):869-880. PubMed ID: 27549124
[TBL] [Abstract][Full Text] [Related]
16. Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma.
Tumino N; Weber G; Besi F; Del Bufalo F; Bertaina V; Paci P; Quatrini L; Antonucci L; Sinibaldi M; Quintarelli C; Maggi E; De Angelis B; Locatelli F; Moretta L; Vacca P; Caruana I
J Hematol Oncol; 2021 Nov; 14(1):191. PubMed ID: 34772439
[TBL] [Abstract][Full Text] [Related]
17. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
Heczey A; Xu X; Courtney AN; Tian G; Barragan GA; Guo L; Amador CM; Ghatwai N; Rathi P; Wood MS; Li Y; Zhang C; Demberg T; Di Pierro EJ; Sher AC; Zhang H; Mehta B; Thakkar SG; Grilley B; Wang T; Weiss BD; Montalbano A; Subramaniam M; Xu C; Sachar C; Wells DK; Dotti G; Metelitsa LS
Nat Med; 2023 Jun; 29(6):1379-1388. PubMed ID: 37188782
[TBL] [Abstract][Full Text] [Related]
18. 4SCAR-GD2-modified T-cell therapy in neuroblastoma with
Xu X; Zhao W; Yue Z; Qin M; Jin M; Chang LJ; Ma X
Pediatr Investig; 2020 Mar; 4(1):55-58. PubMed ID: 32851343
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
20. Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia.
Zhang H; Wang P; Li Z; He Y; Gan W; Jiang H
Clin Cancer Res; 2021 Jul; 27(13):3549-3555. PubMed ID: 33832948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
